Authors : Verma Muskan Sanjay

Volume/Issue : Volume 10 - 2025, Issue 10 - October

Google Scholar : https://tinyurl.com/4pb8t47c

Scribd : https://tinyurl.com/mtsjbwck

DOI : https://doi.org/10.38124/ijisrt/25oct1319

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : In recent years, cancer care has experienced a transformative shift, with innovative approaches redefining diagnosis and therapeutic strategies. This abstract delves into the evolving landscape of oncology, highlighting the importance of integrating advanced technologies and interdisciplinary methodologies. By leveraging comprehensive datasets from genomic studies, pathology, and clinical outcomes, modern techniques have enabled earlier detection and more accurate staging of various cancer types. Moreover, personalized treatment protocols are now tailored to individual patient profiles, enhancing the precision of interventions and improving overall outcomes. This paradigm shift not only offers new avenues for patient care but also poses ethical and logistical challenges that necessitate collaboration among healthcare professionals, researchers, and ethicists. As we progress in this new era of cancer treatment, ongoing research and development are crucial to unlocking the full potential of these innovations, ultimately aiming to enhance clinical decision- making and quality of life for patients. This study emphasizes the necessity for continued exploration and adaptation of emerging methodologies within oncology, advocating for a comprehensive approach that balances innovation with the complexities introduced by these advancements.

References :

1. Bassam Abdul, Ali Haider Mohammed, Souheil Hallit, Diana Malaeb and Hassan Hosseini (Placeholder1) https://doi.org/10.3389/fonc.2025.1475893
2. Buzza Harris*Department of Medical Oncology, Monash University, VIC 3168, Australia  The Role of AI in Precision Oncology
3. Jolene Li Ling Chia, George Shiyao He, Kee Yuen Ngiam, Mikael Hartman and Serene Si Ning Goh; https://doi.org/10.3390/cancers17020197
4. J Solomon Benjamin, M Thomas, Chee K Lee, Michelle M Cummins, Lucille Sebastian, Mandy LBallinger, R John Simes, Emily Collignon, Olivia MH Turnbull, Sonia Yip, Rachael L Morton, Chirs Brown, Patrick J Wheeler, Malinda Itchins and Nick Pavlakis https://doi.org/10.2217/fon-2023-0366
5. Mitsudomi T, MoritaS, YatabeYet al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase III trial. The Lancet Oncology11(2), 121–128 (2010).
6. Rosell R, Carcereny E, GervaisRet al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase III trial. The Lancet Oncology13(3), 239–246 (2012).
7. Wu Y-L, ZhouC, LiamC-Ket al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study†. Ann. Oncol.26(9), 1883–1889 (2015).
8. Schwaederle M, ZhaoM, LeeJJet al. Impact of precision medicine in diverse cancers: a meta-analysis of Phase II clinical trials. J. Clin. Oncol.33(32), 3817–3825 (2015).
9. National Comprehensive Cancer Network, Inc. NCCN Guidelines for Non-Small Cell Lung Cancer. Version 4.2019. www.nccn.org/professionals/physician_gls/default.aspx 
10. Singal G, MillerPG, Agarwala Vet al. Association of patient characteristics and tumour genomics with clinical outcomes among patients with non-small-cell lung cancer using a clinic genomic database. JAMA321(14), 1391–1399 (2019).
11. Ettinger DS, WoodDE, Aisner Let al. non-small-cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compreh. Cancer Network20(5), 497–530 (2022).
12. Hendriks L, KerrK, MenisJet al. non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol.34(4), 358–376 (2023).
13. Thavaneswaran S, SebastianL, BallingerMet al. Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers. Med. J. Aust.209(8), 354–355 (2018) https://doi.org/10.5694/mja18.00227
14. Husereau D, DrummondM, AugustovskiFet al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ376, e067975 (2022).
15. Australian Institute of Health and Welfare. Cancer Data in Australia. Thorn J C, Davies CF, Brookes S Tet al. Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey. Value Health24 www.aihw.gov.au/reports/cancer/cancer-data-in-australia/  
16. DJ Stewart, R Kurzrock: Cancer: The road to Amiens J Clin Oncol ,2009
17. D Hanahan, RA Weinberg: Hallmarks of cancer: The next generation Cell ,2011
18. JE Dancey, PL Bedard, N Onetto, etal: The genetic basis for cancer treatment decisions Cell 148: 409– 420,2012
19. KM Wong, TJ Hudson, JD McPherson: Unraveling the genetics of cancer: Genome sequencing and beyond Annu Rev Genomics Hum Genet 12: 407– 430,2011
20. F Montemurro, G Valabrega, M Aglietta: Trastuzumab treatment in breast cancer N Engl J Med 354: 2186,2006
21. CA Hudis: Trastuzumab: Mechanism of action and use in clinical practice N Engl J Med 357: 39– 51,2007.
22. JA Incorvati, S Shah, Y Mu, etal: Targeted therapy for HER2 positive breast cancer J Hematol OncolJ Hematol Oncol 6: 38,2013
23. LG Boros, WN Lee, M Cascante: Imatinib and chronic-phase leukemias N Engl J Med 347: 67– 68,2002
24. R Said, DS Hong, CL Warneke, etal: P53 mutations in advanced cancers: Clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy Oncotarget 4: 705– 714,2013
25. F Janku, DA Berry, J Gong, etal: Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009 Clin Cancer Res 18: 6356.